While Verona Pharma Plc ADR has underperformed by -0.75%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VRNA rose by 103.27%, with highs and lows ranging from $99.01 to $14.14, whereas the simple moving average jumped by 73.85% in the last 200 days.
On April 28, 2025, TD Cowen started tracking Verona Pharma Plc ADR (NASDAQ: VRNA) recommending Buy. A report published by Cantor Fitzgerald on April 21, 2025, Initiated its previous ‘Overweight’ rating for VRNA. ROTH MKM also rated VRNA shares as ‘Buy’, setting a target price of $68 on the company’s shares in an initiating report dated January 10, 2025. Wells Fargo Initiated an Overweight rating on October 03, 2024, and assigned a price target of $50. Jefferies initiated its ‘Buy’ rating for VRNA, as published in its report on May 22, 2023. Wedbush’s report from September 19, 2022 suggests a price prediction of $27 for VRNA shares, giving the stock a ‘Outperform’ rating. Piper Sandler also rated the stock as ‘Overweight’.
Analysis of Verona Pharma Plc ADR (VRNA)
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Verona Pharma Plc ADR’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -72.73% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 8.73, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and VRNA is recording an average volume of 1.41M. On a monthly basis, the volatility of the stock is set at 3.68%, whereas on a weekly basis, it is put at 2.97%, with a gain of 3.83% over the past seven days. Furthermore, long-term investors anticipate a median target price of $110.45, showing growth from the present price of $94.4, which can serve as yet another indication of whether VRNA is worth investing in or should be passed over.
How Do You Analyze Verona Pharma Plc ADR Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 9.90%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 76.23% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
VRNA shares are owned by institutional investors to the tune of 76.23% at present.
